Sensitive skin
Conditions
Interventions
Control Group:Microneedle/Roller-assisted delivery of Normal Saline
Study Group:Microneedle/Roller-assisted delivery of Dirui? Time Essence
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Aged 30-55 years, in good general health, regardless of gender; 2. Presence of facial erythema, self-perceived sensitive skin, and a positive reaction to the Lactic Acid Stinging Test (total score >= 3); 3. Willing to sign the informed consent form, consent to facial photography, and available to cooperate with the full study schedule; 4. Willing and able to refrain from using other restorative skincare products or cosmetics, and avoid other facial interventions (such as medications, injections, or laser treatments) throughout the study period; 5. Willing to practice strict sun protection and avoid excessive sun exposure; 6. Agree to maintain a regular and healthy lifestyle during the trial; 7. Voluntarily participate in this clinical study and willing to accept long-term follow-up.
Exclusion criteria
Exclusion criteria: 1. Use of any topical drugs in the test site within the past 2 months; 2. Those who have participated in similar facial trials, oral drug trials or other clinical trials within the past 2 months; 3. Any medical aesthetic treatment that affected the skin condition in the past 3 months, such as brushing acid, photon rejuvenation, fractional laser, etc.; 4. Use of antihistamines in the past week or immunosuppressants in the past month; 5. There are obvious scars, pigments, atrophy, port wine stain, sunburn, wounds, wear, tattoos or other defects in the skin test site or accessories, which affect the judgment of the test results; 6. Patients with scar constitution. 7. Patients with unhealed inflammatory skin diseases; 8. Known to be allergic to the ingredients of this product; 9. Long-term exposure to outdoor sunlight due to work or other reasons; 10. Patients receiving treatment for asthma or other chronic respiratory conditions; 11. Patients with insulin-dependent diabetes; 12. Those who received anticancer chemotherapy in the past 6 months; 13. Patients with immunodeficiency or autoimmune diseases; 14. Patients with other iatrogenic problems that may affect the test results (such as history of bleeding and coagulopathy, severe hyperglycemia, hypertension, hyperlipidemia, or other major medical conditions); 15. Pregnant or lactating women; 16. Patients with mental disorders or inability to communicate. 17. Non-volunteer participants or patients who cannot complete the specified trial content as required, or other patients who have participated in other clinical trials are considered unsuitable by the investigators;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lactic Acid Stinging Test (LAST);The improvement of sensitive muscle repair was compared between the two groups after 3 months of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| The improvement of objective indicators of skin barrier;The degree of improvement of objective indicators of skin inflammation;Patient satisfaction assessment;Safety assessment; | — |
Countries
China
Contacts
Public ContactCuihong Lian
Shenzhen Second People's Hospital
Outcome results
None listed